Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Vitamin D supplementation was significantly more common among PwMS compared with HCs (88% vs 47%, p=0.02), with a higher average daily dose (77 µg vs 13 µg, p<0.001).

Source: Baseline characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Participants were allowed to continue first-line disease-modifying therapies (DMTs), including interferon-β preparations, glatiramer acetate, teriflunomide and dimethyl fumarate.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Immunometabolic profiling in menopausal women with multiple sclerosis: the role of adipokines and hormone therapy

Study design awaiting verification · BMJ Neurology Open · 2025

Original publication title

Immunometabolic profiling in menopausal women with multiple sclerosis: the role of adipokines and hormone therapy

Laura Juutinen; Katja Ahinko; Sanna Hagman; Tarja Kokkola; Sari Kärkkäinen; Olli Jääskeläinen; Mari Hämäläinen; Pabitra Basnyat; Julia Vistbacka; Sanna-Kaisa Herukka; Eeva Moilanen; Marja-Liisa Sumelahti

Copyright © Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Adipokine imbalance and lower vitamin D levels were associated with systemic inflammation in PwMS. Adipsin emerged as a promising biomarker, with potential relevance for disease monitoring and therapeutic modulation via hormonal pathways. These findings support further exploration of multibiomarker profiling to guide personalised care in menopausal MS.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Menopausal changes in adipose tissue distribution and adipokine profiles may influence immune activity in multiple sclerosis (MS). We investigated relationships between adipokines, inflammation and disease severity in menopausal women with MS and evaluated changes in adipokines during menopausal hormone therapy (MHT).

Source: Background

Abstract: What methods does the paper describe?

16 menopausal women with MS (participants with MS, PwMS) and 15 age-matched healthy controls were assessed for the associations of adipokines with inflammatory markers, and clinical, radiological and fluid biomarkers of MS severity. Adipokine levels were monitored over 1 year of oral MHT in baseline-controlled design.

Source: Methods

Abstract: Results

In PwMS, body mass index and leptin-to-adiponectin ratio correlated with circulating high-sensitivity C reactive protein (hs-CRP), tumour necrosis factor (TNF)-α and interleukin-6 (ρ=0.51 to 0.66, p<0.05). The associations with hs-CRP and TNF-α were independent of age, disease duration, follicle-stimulating hormone and vitamin D. Serum vitamin D inversely correlated with hs-CRP, TNF-α and interferon-γ (ρ=: 0.64 to 0.65, p<0.01). Adipsin showed strong correlation with neurofilament light chain (ρ=0.72, p=0.002) and decreased during MHT (3 months: p=0.007; 12 months: p=0.04).

Source: Results

Abstract: Conclusions

Adipokine imbalance and lower vitamin D levels were associated with systemic inflammation in PwMS. Adipsin emerged as a promising biomarker, with potential relevance for disease monitoring and therapeutic modulation via hormonal pathways. These findings support further exploration of multibiomarker profiling to guide personalised care in menopausal MS.

Source: Conclusions
Authors’ abstract

Abstract

Background

Menopausal changes in adipose tissue distribution and adipokine profiles may influence immune activity in multiple sclerosis (MS). We investigated relationships between adipokines, inflammation and disease severity in menopausal women with MS and evaluated changes in adipokines during menopausal hormone therapy (MHT).

Methods

16 menopausal women with MS (participants with MS, PwMS) and 15 age-matched healthy controls were assessed for the associations of adipokines with inflammatory markers, and clinical, radiological and fluid biomarkers of MS severity. Adipokine levels were monitored over 1 year of oral MHT in baseline-controlled design.

Results

In PwMS, body mass index and leptin-to-adiponectin ratio correlated with circulating high-sensitivity C reactive protein (hs-CRP), tumour necrosis factor (TNF)-α and interleukin-6 (ρ=0.51 to 0.66, p<0.05). The associations with hs-CRP and TNF-α were independent of age, disease duration, follicle-stimulating hormone and vitamin D. Serum vitamin D inversely correlated with hs-CRP, TNF-α and interferon-γ (ρ=: 0.64 to 0.65, p<0.01). Adipsin showed strong correlation with neurofilament light chain (ρ=0.72, p=0.002) and decreased during MHT (3 months: p=0.007; 12 months: p=0.04).

Conclusions

Adipokine imbalance and lower vitamin D levels were associated with systemic inflammation in PwMS. Adipsin emerged as a promising biomarker, with potential relevance for disease monitoring and therapeutic modulation via hormonal pathways. These findings support further exploration of multibiomarker profiling to guide personalised care in menopausal MS.

Publication and source details

Original title: Immunometabolic profiling in menopausal women with multiple sclerosis: the role of adipokines and hormone therapy

Laura Juutinen; Katja Ahinko; Sanna Hagman; Tarja Kokkola; Sari Kärkkäinen; Olli Jääskeläinen; Mari Hämäläinen; Pabitra Basnyat; Julia Vistbacka; Sanna-Kaisa Herukka; Eeva Moilanen; Marja-Liisa Sumelahti

BMJ Neurology Open · 2025

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Additional supplemental material is published online only. To view, please visit the journal online (https://doi.org/10.1136/bmjno-2025-001295).

None declared.

Laura Juutinen; laura.juutinen@tuni.fi
Copyright © Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.2025https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. Finnish MS Foundation N/A Tampere University Hospital Medical Fund 9T0059U005 http://dx.doi.org/10.13039/501100002341Research Council of Finland 330707335937358045 Novartis Finland Oy N/A

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:44:07.033161+00:00

DOI: 10.1136/bmjno-2025-001295 · PMC12684142